Netscientific Share Discussion Threads

[loafofbread] 14/3/2023 15:25

First news in over 2 years!

Six new patents protecting Glycotest’s HCC Panel test have been issued or allowed in the United States, Europe, China, Taiwan, Japan, and Mexico.
MARCH 1, 2023-NEWS-NO COMMENTS-POSTED BY GLYCOTEST

[kingston78] 14/3/2023 11:47

Many investors don't see the big picture and have a longer term perspective. They trade short term, making little money here but losing money there. Patience will pay off.

[blakieboy7] 14/3/2023 09:40

We need updates to get NSCI moving

[loafofbread] 14/3/2023 09:08

A couple of mid tier bio takeovers in the USA yesterday.

Just under 300% premiums.

I follow a number of the US bio investors on twitter and almost all have PDSB in their top 3 of expected deal makers.

Still think we will wake up to PDSB being sold at $25/30 and NSCI having £25/30M in cash which will double the share price and then some.

None of that takes into account he rest of the portfolio which seems to be doing great guns. You can add another £10M or zero for Glycotest. Makes no difference.

[blakieboy7] 10/3/2023 08:02

It feels like an eternity since we had any kind of meaningful update

[loafofbread] 09/3/2023 23:10

Worth an RNS reach just to remind us about our other investments?

VORTEX BIOTECH HOLDINGS LTD OPENS LABORATORY AT THE LONDON CANCER HUB
09.03.2023 by Anete Merhele
Site also home to The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Lab to drive innovation to be leader in circulating tumour cell (CTC) capture technology

EMV Capital (“EMVC”), the award-winning VC investor specialising in early stage high-growth deep tech companies in the life science, sustainability, and industrials sectors in the UK and internationally, is delighted to report that its portfolio company, Vortex Biotech Holdings Ltd (”Vortex”;), has opened a laboratory at The London Cancer Hub’s Innovation Gateway, in support of its next phase of growth.

The new laboratory sets Vortex firmly on the path to be the innovation leader in circulating tumour cell (CTC) capture technology, which greatly improves therapeutic decisions and saves lives.

The Innovation Gateway is a cutting-edge incubator space for life sciences companies. It is based at The London Cancer Hub in Sutton, which is already home to The Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust – which together rank in the world’s top four centres for cancer research and treatment. Vortex already has laboratory facilities in California.

Vortex has developed a “no touch” microfluidic chip technology which captures intact, label-free, and pure CTCs from blood, with high yields. These CTCs can then be analysed using a range of downstream workflows that help characterise them, providing researchers and clinicians with access to critical insights from whole cancer cells which underpin one of the main causes of metastasis, treatment resistance and disease recurrence. Vortex is part-owned by NetScientific plc, the parent company of EMVC.

Paul Jones, CEO of Vortex, commented:

“The establishment of a new laboratory in London, together with our laboratory facility in California, opens up the path towards our next phase of growth; to set up CTC Centres of Excellence with associated lab services for biopharma customers.

“This new strategy will allow us to deliver a step change in the use of CTCs to inform oncology treatment and monitoring. Longer term, Vortex will look to build on academic and industry engagement to open an interface into clinical health systems around the world.”

Andy Carr, Business Development Manager at The Institute of Cancer Research, London, said:

“It is a pleasure to welcome Vortex to the Innovation Gateway, and we are sure they will make a great contribution to our growing cancer-focused life sciences community here in Sutton. We are confident that new companies like Vortex, in collaboration with academics and clinicians already based here The London Cancer Hub, will make new research breakthroughs that lead to the development of new cancer treatments.”

Dr Ilian Iliev, Managing Director of EMV Capital and Chairman of Vortex, added:

“We are very pleased with Paul and his team’s progress in developing CTC technology with the aim of improving cancer treatment, monitoring disease more effectively, and ultimately improving outcomes for cancer patients. Opening a lab in the UK at such a prestigious cancer research and treatment hub will only serve to accelerate the opportunity.

“We are further bolstered by research¹ showing the tremendous growth of the market in which Vortex operates; with the global liquid biopsy market valued at USD 8.1 billion in 2021 and projected to surpass USD 26.2 billion by 2030.

“We wish Paul and his team well in their new laboratory, and we look forward to their continued advances toward Vortex’s next stage of growth, and execution on the Centres of Excellence strategy.”

¹ Liquid Biopsy Market Size, Growth, Trends, Report 2022 to 2030, Precedence Research.

[loafofbread] 09/3/2023 23:04

16 August 2022

NetScientific plc

("NetScientific", the "Group" or the "Company")

Completion of acquisition of 30% stake in Vortex Biotech Holdings (Vortex)

and

appointment of new Vortex CEO

To drive commercial opportunities and develop an industry leading solution

NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, is pleased to announce, further to its announcement of 6 May 2022, that it completed yesterday its acquisition of a 30 per cent. stake in Vortex. Additionally, Vortex has recently appointed Paul Jones as its new Chief Executive Officer.

Vortex is focused on developing its position in the multi-billion dollar oncology liquid biopsy market, which is estimated to grow at 14% CAGR by 2030*. Vortex's core technology allows for the capture and isolation of high quality Circulating Tumour Cells ("CTCs") from blood samples. Paul will lead Vortex's growth strategy around this core technology with the aim of developing it into an industry leading platform that will help accelerate the translation of research insights into the clinic and help deliver to an affordable population health agenda.

Paul has previously worked at Illumina, Inc., the global leader in genome sequencing, where he was the Head of Population Genomics. He led the team that created, developed and actively managed large-scale programmes across more than 50 different countries. Prior to this, Paul was the founding CEO of Genomic Enterprises, the arm of Genomics England responsible for all commercial aspects of the 100,000 Genomes Project. Paul has also held roles as Director and Leader of Global Life Sciences at Cisco and Head of Global eMarketing & eSales at Novartis. Early in his career he was a Management Consultant at PwC, focused on life sciences. Paul completed a Certificate in Private Equity at Imperial College, London in 2022, an MBA from the University of Sheffield, in 1992, and an undergraduate degree majoring in physiology in 1989.

NetScientific's completed acquisition of its 30% stake in Vortex positions the Group well to take advantage of the substantial upside potential for an innovative technology platform in the liquid biopsy space. The Vortex multi-phased growth strategy will include product and cartridge sales; a services lab business catering to cancer research efforts (both academic and industry); and in the longer term laboratory developed tests to support key prognostic, diagnostic, therapy selection and potentially predictive markers of relevance to everyday clinical practice.

Vortex' VTX-1 platform has been placed and used for KOL published research in leading University and Research centres in the US, UK and EU, including UCLA, UC Berkeley, Stanford University, Ghent University (Belgium), University of Maryland, and Ecole Polytechnique Federale de Lausanne. In addition, Vortex is now seeing growing interest from pharma and biotech clients. The company has developed several workflow integrations of the VTX-1 instrument with third party instruments, opening further commercialisation opportunities.

Dr Ilian Iliev, CEO of NetScientific PLC and Chairman of Vortex, commented: "We are pleased to have completed the acquisition of our stake in Vortex, and delighted to welcome Paul to the Vortex team. We are excited by the growth potential of the company in this rapidly growing and maturing market and see Paul as an integral part of achieving our ambitious goals. He brings a wealth of industry experience, which will be invaluable as Vortex develops its operations. We believe that Vortex offers significant upside and the ability to commercialise the technology in the US and Europe will drive significant value."

Paul Jones, CEO of Vortex Biotech Holdings, added: "I've worked for many years to enable a vision of affordable population health. Recent developments in liquid biopsy will enable earlier disease detection, support personalised medicine and allow far easier ongoing disease monitoring - making this vision a realistic prospect even in the short term. It is a privilege to be given the opportunity to lead Vortex and show how we can make a real difference for patients suffering from cancer across the world."

[loafofbread] 05/3/2023 21:47

Friday afternoon sellers thought PDSB was going down on the open but ended up 4%.

Perhaps they will buy them back tomorrow?

[blakieboy7] 28/2/2023 09:10

Well Loaf, that Proaxis update never materialised. Whoever you spoke to gave you duff info. Hopefully it will land soon

[blakieboy7] 27/2/2023 13:37

Big news for PDSB - htTps://quantisnow.com/insight/4120398

[kingston78] 24/2/2023 10:07

There is short term profit taking, but it would appear to be that 80 p is now the new base line from which the share will propel upwards on good news flow.

[loafofbread] 23/2/2023 19:13

I've been told we will get a ProAxis business update in February (same as last year but a bit later than January 22)

Then full NSCI results in March.

PDSB presenting at 3 conferences in the next month with 3 major results also due.

[blakieboy7] 23/2/2023 18:17

I thought the results weee due, but I think I'm mistaken - I think the results are due in March

[kingston78] 23/2/2023 17:24

Does anyone know whether the company will make some kind of announcement soon?

[loafofbread] 20/2/2023 16:34

As i mentioned on Friday the ProAxis website is almost live.

Looking much more professional and a great shop window going forward.

They are having issues with security so make sure the kids aren't looking over your shoulder!!

[blakieboy7] 20/2/2023 11:53

Advfn is having technical problems and we'll behind on trades etc

[investordave] 20/2/2023 11:29

Something afoot folks...

[blakieboy7] 20/2/2023 09:52

Nice start to the week

[blakieboy7] 17/2/2023 16:51

Hopefully results next week too

[loafofbread] 17/2/2023 16:50

I have a feeling the new Proaxis website is finally on it's way.

Code changed on the existing one so maybe up for Monday?

[kadvfn1] 15/2/2023 17:39

hardly any volume today...

[blakieboy7] 15/2/2023 17:19

What a disappointing end to the day

[blakieboy7] 15/2/2023 09:52

Results can't be far away now

[loafofbread] 14/2/2023 15:17

10M

EMV Capital
@EMVCapital
As we embark on a new year, we remain committed to back strong teams fostering innovation across the life sciences, sustainability, and industrials sectors.

In the first 2023 edition of our newsletter, we share some insights and updates with you⏩ hxxps://us7.campaign-archive.com/?e=%5BUNIQID%5D&u=9712c73c5f36f498acb792a7a&id=1618c344eb

[loafofbread] 14/2/2023 09:47

Proaxis rebranding, company update and new website should be out this week.

The new company premises in the USA is handling all new 7 product lines so they should have something worthwhile to say.